RGA 6101 — Therapeutic Product Development: A Regulatory Overview

4 semester hoursGraduateLecture

Examines every step of the biotherapeutic development and regulation process within the U.S. FDA's Center for Biologic Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). Enrolled students receive didactic instruction from product formulation, product development, and preclinical testing perspectives through postmarketing adverse experience reporting. Offers students an opportunity to study FDA standards for nonclinical testing-quality assurance issues and good laboratory practice, investigational new drug (IND) applications, therapeutic market applications and review processes designed to speed therapeutic product review, as well as current good manufacturing practice and operations management regulations.

Prerequisites

Unlocks

RGA 6203, RGA 6204, RGA 6207, RGA 6210, RGA 6215, RGA 6217, RGA 6219, RGA 6223, RGA 6224, RGA 6233, RGA 6235, RGA 6308, RGA 6380, RGA 6410, RGA 6415, RGA 6435, RGA 6440, RGA 6461, RGA 6475, RGA 6480, RGA 6500, RGA 6630, RGA 6670, RGA 6680

Courses that list RGA 6101 in their prerequisites.

Links

Official catalog (RGA course descriptions) · All RGA courses · Plan it at numap.app

More

{
 "retired": true,
 "retiredSince": "2026-09-03"
}